Please assess the completion status of the following clinical trial:

Trial Title: S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of multiple myeloma (MM)~  * Active disease~* Relapsed or refractory disease after ≥ 1 prior therapy for MM, that may have included autologous or allogeneic stem cell transplantation~  * Relapse is defined as the occurrence of any of the following during or after prior treatment:~    * Myeloma protein level increase by \> 100% from the lowest previously recorded level~   * Myeloma protein level increase above the defined response criteria for partial remission~   * Reappearance of any myeloma peak that had disappeared during the prior treatment~   * Increase in the size and number of lytic bone lesions and/or focal lesions by x-ray, MRI, positron emission tomography, and/or CT scan~ * Refractory disease is defined as no response (i.e., not achieving complete remission, remission, or partial remission) to prior therapy~* Measurable disease~* No evidence of POEMS (polyneuropathy, organomegaly, endocrinopathy, presence of M-protein, and skin changes) syndrome~* Must be registered on protocol SWOG-S0334~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-2 (unless due to bone pain)~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count \> 1,000/mm\^3~* Platelet count \> 50,000/mm\^3~Hepatic~* AST or ALT ≤ 3 times upper limit of normal (ULN)~* Bilirubin ≤ 3 times ULN~Renal~* Creatinine clearance \> 30 mL/min~Cardiovascular~* No New York Heart Association class III or IV congestive heart failure~* No myocardial infarction within the past 6 months~* No poorly controlled hypertension~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile female patients must use effective double method contraception for ≥ 4 weeks before, during, and for ≥ 4 weeks after completion of study treatment (during and for 4 weeks after completion of study treatment for male patients)~* No blood, ova, or sperm donation during study treatment~* No active infection requiring antibiotics~* No neurotoxicity ≥ grade 2~* No diabetes mellitus~* No other serious medical or psychiatric illness that would preclude study treatment~* No other malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~Chemotherapy~* At least 14 days since prior chemotherapy (28 days for nitrosoureas) and recovered~Endocrine therapy~* Not specified~Radiotherapy~* At least 14 days since prior radiotherapy and recovered~Surgery~* Not specified~Other~* No prior bortezomib alone or combined with thalidomide~* Concurrent participation on protocol SWOG-S0309 allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- bortezomib with thalidomide and dexamethasone (Type: EXPERIMENTAL): bortezomib with thalidomide and dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues